Bristol-Myers Squibb: Our Partners
 
Our Partners

Bristol-Myers Squibb has a long history of, and deep experience in, collaborating with the right scientific and commercial partners to advance our research and development portfolio. Together with our partners, we have built some of the most successful products in their respective therapeutic areas. Previous collaborations with companies including Sankyo (PRAVACHOL®, 1985), Yale University (ZERIT®, 1987), National Cancer Institute (TAXOL®, 1991), Sanofi (PLAVIX® and AVAPRO®, 1993), Lipha (GLUCOPHAGE®, 1994), Otsuka (ABILIFY®, 1999), Gilead (ATRIPLA®, 2004), Pfizer (ELIQUIS®, 2007) and Ono (OPDIVO®, 2014) have produced treatments that have served millions of patients worldwide.

Today, partnering continues to be a critical element in our ability to deliver transformational medicines to patients in areas of high unmet medical need. Below is a sample of our recent collaborations which provide both great scientific and commercial value, and current or potential treatments for the patients we serve.


Recent Select Specialty Partnerships

Recent-Select-Speciality-Partnerships

Trademarks are the property of their respective owners






Recent Select Immuno-Oncology Partnerships

Recent-Select-Immuno-Oncology-Partnerships

Trademarks are the property of their respective owners

 
 
 
 


You are leaving BMS.com to go to the Amylin Job Search and application tool. IMPORTANT TO NOTE: This may require a separate login and password than what is used for the Bristol-Myers Squibb search and application process.